ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
HUTCHMED and AstraZeneca Begin Phase II Trial of ORPATHYS® in Gastric Cancer
July 29, 2021HUTCHMED and AstraZeneca PLC have initiated a Phase II study of ORPATHYS® (savolitinib), an oral, potent, and highly selective small-molecule inhibitor of MET, a receptor tyrosine kinase, in patients with advanced or metastatic MET amplified gastric ... -
HUTCHMED Announces NMPA Approval of Surufatinib (Sulanda(R) in China) for Advanced Pancreatic Neuroendocrine Tumors
June 22, 2021HUTCHMED (China) Limited announces that surufatinib has been granted approval for drug registration by the National Medical Products Administration of China ("NMPA") for the treatment of advanced pancreatic neuroendocrine tumors ("pNETs").
Pharma Sources Insight January 2025
